ABCD² Score Calculator for TIA Stroke Risk

How to Use This Calculator

1. Select Age ≥ 60, BP elevation, clinical features (unilateral weakness = 2pts), TIA duration (≥60 min = 2pts), and diabetes.
2. ABCD² score (0-7), 7-day stroke risk, and risk category calculate instantly.
3. Use the Urgent Management tab for admission decision and workup guidance.

Formula

Example

Frequently Asked Questions

• What is the ABCD² score and how was it developed? ▼
  The ABCD² score is a validated clinical prediction tool designed to estimate the short-term risk of stroke following a transient ischemic attack (TIA). It was derived by Johnston et al. from the California and ABCD score studies and published in Lancet in 2007. The score was developed by combining two previously validated prediction rules — the California score and the ABCD score — into a single instrument using pooled data from four independent TIA cohorts totaling over 2,000 patients. The acronym describes its five components: Age 60 years or older (1 point), Blood pressure 140/90 mmHg or higher at first assessment (1 point), Clinical features of the TIA including unilateral weakness (2 points) or speech disturbance without weakness (1 point), Duration of TIA symptoms at least 60 minutes (2 points) or 10-59 minutes (1 point), and Diabetes mellitus (1 point). The total score ranges from 0 to 7. In the derivation cohort, patients with scores 0-3 had a 7-day stroke risk of approximately 1%, those with scores 4-5 had a 4.1% risk, and those with scores 6-7 had an 8.1% 7-day stroke risk. The score is designed to identify which TIA patients require urgent evaluation and admission versus those who can be safely managed in an outpatient TIA clinic setting.
• What are the ABCD² risk tiers and what do they mean clinically? ▼
  The ABCD² score divides TIA patients into three risk tiers with distinct clinical implications. Low risk (score 0-3) corresponds to an approximately 1.0% 7-day stroke risk. These patients may be appropriate for an expedited outpatient TIA clinic evaluation within 24 hours rather than emergency admission, provided no high-risk features are identified on clinical assessment. However, several important caveats apply: even low ABCD² patients have a non-trivial absolute stroke risk, and immediate aspirin plus statin should be started regardless of score. Moderate risk (score 4-5) corresponds to a 7-day stroke risk of approximately 4.1%. These patients should generally be admitted or evaluated in a TIA unit capable of same-day brain imaging, EKG, carotid imaging, and echocardiogram, with immediate secondary prevention initiated. High risk (score 6-7) corresponds to a 7-day stroke risk of approximately 8.1%. These patients should be admitted immediately to a stroke unit or monitored bed, with urgent complete evaluation including diffusion-weighted MRI to identify any cortical or subcortical infarction that would reclassify the event as stroke rather than TIA. Contemporary guidelines note that high-risk TIA is a neurological emergency with a stroke risk comparable to STEMI.
• What are the limitations of the ABCD² score in current clinical practice? ▼
  Despite its widespread adoption, the ABCD² score has important limitations that have become more apparent as TIA management has evolved. First, the score does not incorporate brain imaging, and a patient with a negative ABCD² score may still have an acute DWI lesion on MRI, reclassifying the event as a small ischemic stroke rather than a true TIA — this dramatically changes management. Second, the score does not capture etiology, particularly cardioembolic sources such as atrial fibrillation or significant carotid stenosis, which are the most important drivers of recurrent stroke risk and the most actionable findings requiring specific treatment (anticoagulation for AFib, endarterectomy or stenting for symptomatic carotid stenosis above 50-70%). Third, multiple validation studies have shown that the ABCD² score has only modest discrimination (c-statistic approximately 0.62-0.72), and studies using more comprehensive workup including MRI have challenged whether ABCD² alone adequately risk-stratifies patients. The 2021 AHA/ASA TIA guidelines now recommend that all TIA patients undergo urgent brain MRI with DWI, cardiac monitoring for at least 24 hours, and vascular imaging regardless of ABCD² score. In this context, ABCD² is best understood as one component of a comprehensive initial assessment, not as a standalone decision tool for admission.
• What is the correct immediate management after a TIA regardless of ABCD² score? ▼
  Regardless of ABCD² score, all patients with a suspected TIA require immediate initiation of secondary stroke prevention. The recommended interventions are based on high-quality evidence from the EXPRESS and SOS-TIA studies, which showed that urgent treatment in TIA clinics reduced 90-day stroke risk by approximately 80% compared to standard care. Immediate interventions that should be started on the same day of TIA diagnosis include: antiplatelet therapy (aspirin 300 mg loading dose immediately, then 75-100 mg daily, combined with clopidogrel 75 mg in the POINT trial for high-risk TIA patients — dual antiplatelet therapy for 21 days in those without AFib); high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg); and blood pressure management if hypertension is present, though caution is advised with aggressive BP reduction within the first 24 hours. If atrial fibrillation is identified on EKG or 24-hour monitoring, anticoagulation should be initiated after ruling out hemorrhagic stroke on imaging. For patients with symptomatic carotid stenosis 50-99% ipsilateral to the TIA, urgent endarterectomy (within 14 days and ideally within 48 hours of high-risk TIA) reduces stroke risk by up to 75% compared to medical therapy alone and represents one of the most effective interventions in stroke prevention.
• How does the ABCD² score relate to the ABCD3-I and ABCD2-I scores? ▼
  The original ABCD² score has been extended in several ways to improve its predictive accuracy by incorporating additional predictors, particularly brain imaging and vascular findings. The ABCD3 score added a sixth criterion: dual TIA (two TIA events within 7 days) worth 2 additional points, extending the range to 0-9. The ABCD3-I score further incorporated ipsilateral carotid stenosis 50% or greater (2 points) and DWI-positive lesion on brain MRI (2 points), extending the range to 0-13 and substantially improving discrimination compared to the original ABCD² (c-statistic approximately 0.82 in some validation cohorts). The ABCD2-I score incorporated only the DWI finding. The consistent finding across these extensions is that acute DWI lesion on MRI is the single most powerful predictor of early stroke recurrence after TIA, with patients with a DWI-positive TIA (sometimes called "TIA with infarction") having a substantially higher recurrence risk than DWI-negative TIA patients with the same ABCD² score. Contemporary AHA/ASA 2021 TIA guidelines acknowledge these extensions but note that the most important step is not which scoring system to use, but ensuring that all TIA patients receive comprehensive urgent evaluation including brain MRI, cardiac monitoring, and vascular imaging, with rapid initiation of all evidence-based secondary prevention measures.

Related Calculators